Cited 185 times in
Nivolumab in NSCLC: latest evidence and clinical potential
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 조병철 | - |
dc.date.accessioned | 2016-02-04T11:35:57Z | - |
dc.date.available | 2016-02-04T11:35:57Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 1758-8340 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/140780 | - |
dc.description.abstract | New insight on the interaction between the immune system and tumor has identified the programmed death-1/programmed death-1 ligand pathway to be a key player in evading host immune response. The immune checkpoint modulator, nivolumab (BMS-936558/ONO-4538), is the first PD-1 inhibitor to gain regulatory approval, for the treatment of patients with unresectable melanoma. This review will discuss results from early phase studies of nivolumab in solid tumors including non-small cell lung cancer (NSCLC) as well as studies of nivolumab in combination with chemotherapy, other immune modulators and molecular targeted therapy in patients with NSCLC. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 85~96 | - |
dc.relation.isPartOf | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Nivolumab in NSCLC: latest evidence and clinical potential | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Raghav Sundar | - |
dc.contributor.googleauthor | Byoung-Chul Cho | - |
dc.contributor.googleauthor | Julie R. Brahmer | - |
dc.contributor.googleauthor | Ross A. Soo | - |
dc.identifier.doi | 10.1177/1758834014567470 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03822 | - |
dc.relation.journalcode | J02720 | - |
dc.identifier.eissn | 1758-8359 | - |
dc.identifier.pmid | 25755681 | - |
dc.identifier.url | http://tam.sagepub.com/content/7/2/85.abstract | - |
dc.subject.keyword | immune checkpoint modulator | - |
dc.subject.keyword | nivolumab | - |
dc.subject.keyword | non-small cell lung cancer | - |
dc.subject.keyword | programmed death-1 | - |
dc.subject.keyword | programmed death-1 ligand | - |
dc.contributor.alternativeName | Cho, Byoung Chul | - |
dc.contributor.affiliatedAuthor | Cho, Byoung Chul | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 7 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 85 | - |
dc.citation.endPage | 96 | - |
dc.identifier.bibliographicCitation | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, Vol.7(2) : 85-96, 2015 | - |
dc.identifier.rimsid | 30306 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.